Italia markets closed

Tibet AIM Pharm. Inc. (002826.SZ)

Shenzhen - Shenzhen Prezzo differito. Valuta in CNY.
Aggiungi a watchlist
8,62+0,11 (+1,29%)
Alla chiusura: 03:04PM CST

Tibet AIM Pharm. Inc.

Yingdu Building
Yingdu Building No. 48 Zhichun Road A Haidian District
Beijing
China
86 10 5873 1208
https://www.emyy.cn

Settore/iHealthcare
SettoreDrug Manufacturers - Specialty & Generic
Impiegati a tempo pieno

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Ke XuGM & ChairmanN/DN/D1978
Mr. Yu ZhangDeputy GM & Non-Independent DirectorN/DN/D1980
Ms. Qianjin LiDeputy GM & Secretary of the Board of DirectorsN/DN/D1977
Ms. Zhou MinFinancial Director & DirectorN/DN/D1987
Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CNY.

Descrizione

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; and NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain, as well as coma, spinal cord injury, cerebral infarction, hemorrhage, etc. It also provides Carbetocin injections for prevention of postpartum hemorrhage; Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.

Governance aziendale

L'ISS Governance QualityScore di Tibet AIM Pharm. Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.